HER2/Neu Positive Recruiting Phase 3 Trials for Pertuzumab (DB06366)

IndicationStatusPhase
DBCOND0037939 (HER2/Neu Positive)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03199885Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast CancerTreatment